Apoptosis
Sarclisa in combination with Carfilzomib and Dexamethasone for patients with relapsed or refractory multiple myeloma, FDA approved
The FDA ( U.S. Food and Drug Administration ) has approved Sarclisa ( Isatuximab ) in combination with Carfilzomib and...
European Commission has approved second indication of Sarclisa for relapsed multiple myeloma in combination with Carfilzomib and Dexamethasone
The European Commission ( EC ) has approved Sarclisa ( Isatuximab ) in combination with Carfilzomib and Dexamethasone ( Kd...
Venetoclax in the treatment of acute myeloid leukemia
Venetoclax ( Venclexta ) in newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a...
Marijuana accelerates growth of HPV-related head and neck cancer
UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...
European Commission has approved Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
The European Commission has approved Venclyxto ( Venetoclax ) in combination with Gazyvaro ( Obinutuzumab ) for the treatment of...
Sarclisa for adults with relapsed and refractory multiple myeloma; European Commission has approved
The European Commission ( EC ) has approved Sarclisa ( Isatuximab ) in combination with Pomalidomide and Dexamethasone ( Pom-Dex...
monarchE trial: Abemaciclib given with endocrine therapy has shown improvement compared to endocrine therapy alone in people whose HR+ HER2- early breast cancer is at a high risk of recurrence
Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...
Venclexta as a chemotherapy-free combination regimen for previously untreated chronic lymphocytic leukemia patients, approved by FDA
The U.S. Food and Drug Administration ( FDA ) has approved Venclexta ( Venetoclax ) in combination with Obinutuzumab (...
Venetoclax chemotherapy-free combination regimen for patients with previously untreated chronic lymphocytic leukemia
Data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months...
Experimental model of multiple sclerosis: preclinical evaluation of the PI3K/Akt/mTOR pathway
The PI3K/AKT/mTOR pathway is an intracellular signalling pathway that regulates cell activation, proliferation, metabolism and apoptosis. Increasing body of data...
FLT3 inhibitors in acute myeloid leukemia
Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...
Combination therapy based on Tafinlar and Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma: approved in European Union
The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment...
Belimumab in systemic lupus erythematosus
In 2016, the National Institute for Health and Care Excellence ( NICE ) approved the use of Belimumab ( Benlysta...
Multiple sclerosis: emerging roles of endothelial cells in pathophysiology and therapy
Multiple sclerosis ( MS ) is increasingly being viewed and studied not only as an immune-mediated demyelinating and neurodegenerative disease...
FDA has granted Priority Review for Venetoclax, an inhibitor of the Bcl-2 protein, in chronic lymphocytic leukemia
The FDA ( Food and Drug Administration ) has accepted the New Drug Application ( NDA ) and granted Priority...
Cardiotoxicity associated with targeted cancer therapies
Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...
HER2+ breast carcinoma: Lapatinib and Trastuzumab shrinks cancer in 11 days after diagnosis
Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs...
Nonalcoholic steatohepatitis: Selonsertib has shown improvement in fibrosis stage in patients with moderate to severe fibrosis
Detailed results from an open-label phase 2 trial evaluating the investigational apoptosis signal-regulating kinase 1 ( ASK1 ) inhibitor Selonsertib...
Arginine-degrading-enzyme therapy may be a useful strategy for treating bladder cancer lacking the enzyme needed for arginine synthesis
With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a...
Neoadjuvant Dasatinib for muscle-invasive bladder cancer: Src inhibition appears ineffective in unselected patients
Preclinical urothelial carcinoma models suggest activity of Dasatinib ( Sprycel ), an oral Src-family kinase ( SFK ) inhibitor. Researchers...